hepdart paper - data analysis

BIT is generating quite a bit of interest at the moment. I had a look at the HepDART presentation (see link below) and did a Fishers Exact Test (stats) for small numbers on the data at 12 weeks. Selected BIT225 400mg plus SOC versus placebo plus SOC. The result is >0.5 - nowhere near a statistically significant difference. So I'd be cautious betting the shop on BIT atm. Numbers in the study are far too small to draw definite conclusions from. So beware of the hype atm. To be fair, the study was not designed to have the power needed to give a yes/no answer on efficacy. Looking somewhat promising but a way to go yet unless the pending HIV study results are truly outstanding.

Antiviral activity and tolerability of BIT225 plus pegylated interferon alfa-2b and weight-based ribavirin for 28 days in HCV treatment-naïve, genotype 1, mono-infected patients